Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells.
about
New advances in targeted gastric cancer treatmentCurrent Molecular Targeted Therapy in Advanced Gastric Cancer: A Comprehensive Review of Therapeutic Mechanism, Clinical Trials, and Practical ApplicationExtracellular Matrix, a Hard Player in AngiogenesisPhase II study of cisplatin/etoposide and endostar for extensive-stage small-cell lung cancer.Recombined humanized endostatin (Endostar) combined with chemotherapy for advanced bone and soft tissue sarcomas in stage IV.Endostar down-regulates HIF-1 and VEGF expression and enhances the radioresponse to human lung adenocarcinoma cancer cells.Recombinant human endostatin normalizes tumor vasculature and enhances radiation response in xenografted human nasopharyngeal carcinoma models.Regulation of Tumor Angiogenesis and Choroidal Neovascularization by Endogenous Angioinhibitors.Clinical significance of serum and tumor tissue endostatin evaluation in operable non-small cell lung cancer.Recombinant human endostatin could eliminate the pro-angiogenesis priority of SP cells sorted from non-small cell lung cancer cells.Endostar-loaded PEG-PLGA nanoparticles: in vitro and in vivo evaluationRecombinant human endostatin endostar suppresses angiogenesis and lymphangiogenesis of malignant pleural effusion in miceNeoadjuvant rh-endostatin, docetaxel and epirubicin for breast cancer: efficacy and safety in a prospective, randomized, phase II study.Anti-angiogenic peptides for cancer therapeuticsTargeting angiogenesis in melanoma: prospects for the futureSuitable carriers for encapsulation and distribution of endostar: comparison of endostar-loaded particulate carriers.The therapeuatic effect of Endostar on soft carotid plaque neovascularization in patients with non-small cell lung cancer.Endostar, a modified recombinant human endostatin, suppresses angiogenesis through inhibition of Wnt/β-catenin signaling pathwayCysteine cathepsins S and L modulate anti-angiogenic activities of human endostatin.GX1-conjugated poly(lactic acid) nanoparticles encapsulating Endostar for improved in vivo anticolorectal cancer treatment.Endostatin improves cancer-associated systemic syndrome in a lung cancer modelEndostar inhibits ascites formation and prolongs survival in mouse models of malignant ascites.Tumor stroma derived biomarkers in cancer.Thoracic perfusion of recombinant human endostatin (Endostar) combined with chemotherapeutic agents versus chemotherapeutic agents alone for treating malignant pleural effusions: a systematic evaluation and meta-analysisGastric carcinoma in China: Current status and future perspectives (Review)Endostatin's emerging roles in angiogenesis, lymphangiogenesis, disease, and clinical applications.Sp1-driven up-regulation of miR-19a decreases RHOB and promotes pancreatic cancer.Synergistic effects of Endostar combined with β-elemene on malignant ascites in a mouse model.Antitumor activity of Endostar combined with radiation against human nasopharyngeal carcinoma in mouse xenograft models.Systematic review and meta-analysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer.Dynamic contrast-enhanced MR imaging in a phase Ⅱ study on neoadjuvant chemotherapy combining Rh-endostatin with docetaxel and epirubicin for locally advanced breast cancerThe efficacy and safety of Endostar combined with chemoradiotherapy for patients with advanced, locally recurrent nasopharyngeal carcinoma.Endostatin and endorepellin: A common route of action for similar angiostatic cancer avengersEndostatin, an angiogenesis inhibitor, ameliorates bleomycin-induced pulmonary fibrosis in rats.Efficacy and safety of extended use of platinum-based doublet chemotherapy plus endostatin in patients with advanced nonsmall cell lung cancerGold Nanoparticle-Mediated Targeted Delivery of Recombinant Human Endostatin Normalizes Tumour Vasculature and Improves Cancer Therapy.Antiangiogenic therapy using endostatin increases the number of ALDH+ lung cancer stem cells by generating intratumor hypoxia.The feasibility of 18F-AlF-NOTA-PRGD2 PET/CT for monitoring early response of Endostar antiangiogenic therapy in human nasopharyngeal carcinoma xenograft model compared with 18F-FDG.Molecular targeting agents associated with transarterial chemoembolization or radiofrequency ablation in hepatocarcinoma treatment.Serum endostatin concentrations are higher in men with symptoms of intermittent claudication.
P2860
Q26738548-CB7A8399-76B3-4135-9089-B65558B8D921Q26765941-4A637FF9-B68C-421E-AC59-7AAAFC9C44E3Q28072886-E3FE0056-8F66-4C82-A074-FDEE9597C31EQ33394192-115A2ED2-5C8E-4D92-89D5-D91B1FAE670AQ33829625-537B00DA-F672-420B-A37F-B01D4E2C75C3Q33897862-1978DB51-0BE4-4414-A483-64D02D5692DCQ34230220-194F0238-BEC6-42DF-A0EC-FC1607D9BEDFQ34230899-D6C1F2DE-5C23-4E45-9B15-A85B3F67FCF6Q34265632-423A7282-C745-4158-9FDB-25659CBD06ECQ34362205-E7C9CF00-093C-4388-A94B-FA9A802F1B32Q34396694-991908DA-4D59-4E0C-8E67-8E5839738812Q34535252-EA0BD5D7-5892-4D64-83D1-259D1BC64F21Q34732915-D2F7A4C1-AACC-4525-8777-80E7C2CA5D98Q35043016-7106DB32-C3A0-4879-9CE3-308AAFECAE5AQ35076316-04A0D3B6-5994-400F-916F-F987249C9601Q35153705-62F55D35-B508-42DF-A300-A22AEB5A776AQ35160832-FA89C732-09C2-428F-B597-DC41B4C18F90Q35260978-5F368FA4-9D75-4B55-886D-789BEB26B148Q35423407-842CEDBF-F23F-4730-89D0-2AAF8227152CQ35679314-E8A47263-3193-44E6-918C-8718DE043542Q35742098-0676A5AB-3C98-4919-AD69-B8E96EE3527DQ35758912-4B62695F-7645-40DD-A64D-3B7C8F075ECBQ35765454-47904423-D13F-46CB-9E04-0C85D826A675Q36191975-FA0D9456-08C9-4E3B-AA97-1CA0E3F7E0BDQ36216823-34876BBA-BC46-4295-87A8-37013319B853Q36220259-41424834-0E98-43CA-AF42-339A4836B2D4Q36232057-5F7B9550-1E0C-4A8D-96FD-A13A91121405Q36285646-E0386482-732C-46BC-8486-E9EA1652A901Q36403182-398EA67F-C8EF-4C1D-97F4-CFB63494FDE9Q36455063-A4E244B6-6246-4DBD-A777-304CFA97DA46Q36540092-E5317F72-B36D-4D93-847C-BA6F6D218B65Q36545328-EB869851-82DC-4CCC-B4E9-EF32F366EDA8Q36578668-5945E8BD-91BA-401F-992B-DF1FDF36CD2FQ36888683-B74B0644-77E1-41EB-98B1-DE9080AEA8EAQ37116858-731CD9B0-CF8A-4825-8F2F-E535478AEF46Q37137190-2C0F1CEB-630A-49D2-9789-BA8D384FA947Q37310622-2015E20A-35EA-4094-8B3A-BB4383C2D4C0Q37317221-342351B8-F027-4400-9282-612DBA433CA0Q37581359-E7B00FA4-C8D4-4537-9EDE-D1D2D6B4E61DQ37588280-C26D75CA-0FED-45C7-804A-D3B8C5C09619
P2860
Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Endostar, a novel recombinant ...... DR/Flk-1 of endothelial cells.
@en
Endostar, a novel recombinant ...... DR/Flk-1 of endothelial cells.
@nl
type
label
Endostar, a novel recombinant ...... DR/Flk-1 of endothelial cells.
@en
Endostar, a novel recombinant ...... DR/Flk-1 of endothelial cells.
@nl
prefLabel
Endostar, a novel recombinant ...... DR/Flk-1 of endothelial cells.
@en
Endostar, a novel recombinant ...... DR/Flk-1 of endothelial cells.
@nl
P2093
P1476
Endostar, a novel recombinant ...... DR/Flk-1 of endothelial cells.
@en
P2093
Qi-dong You
Qing-Long Guo
P356
10.1016/J.BBRC.2007.06.155
P407
P577
2007-07-10T00:00:00Z